Clinical Trials · NCT05617885
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Praful Ravi, MB BCHir, MRCP
- Enrollment
- 9
- Start date
- Aug 2023
- Locations
- 1 site, United States
- Primary endpoint
- Phase 1 - Maximum Tolerated Dose (MTD)